We learned from discussions with Weber et al. that mouse p19 ARF contains two independent MDM2-binding regions within the exon-1β-encoded sequences [14] . To define the MDM2-binding domains in human p14 ARF , we expressed fragments of p14 ARF (Figure 1a) in the active site loop of thioredoxin (Tx) [13, 15] . Consistent with previous studies of mouse and human ARF [9,12], we found that Tx-ARF1-64, corresponding to the region of p14 ARF 
Results and discussion
We learned from discussions with Weber et al. that mouse p19 ARF contains two independent MDM2-binding regions within the exon-1β-encoded sequences [14] . To define the MDM2-binding domains in human p14 ARF , we expressed fragments of p14 ARF (Figure 1a ) in the active site loop of thioredoxin (Tx) [13, 15] . Consistent with previous studies of mouse and human ARF [9, 12] , we found that Tx-ARF1-64, corresponding to the region of p14 ARF expressed from exon 1β, retained the ability to bind cotransfected MDM2 (Figure 1b, left) . This activity was localized to the amino-terminal half of this region of p14 ARF ; Tx-ARF1-34 retained the ability to bind MDM2 (Figure 1b , left), but this was lost in Tx-ARF35-64 (data not shown). Comparison of human p14 ARF with mouse p19 ARF revealed that the highest level of conservation between the two proteins was within the first 22 amino acids. Analysis of smaller p14 ARF peptides showed that residues 1-22 retained the ability to bind MDM2, whereas Tx-ARF23-44 and Tx-ARF56 -64 showed no evidence of binding (Figure 1b, left) . Analysis of the exon-2-encoded sequences of p14 ARF in Tx-ARF65-132 revealed a second MDM2-binding site, although comparison of the coprecipitated Tx-ARF proteins with the total amount in the cell showed that the Tx-ARF65-132 fragment bound MDM2 much less efficiently than Tx-ARF1-22 (Figure 1b, right) . Two MDM2-binding regions have also been described in p19 ARF but, in the mouse protein, both MDM2-interacting domains are in the sequences encoded by exon 1β [14] . Interestingly, of the two MDM2-interacting domains in the amino terminus of p19 ARF , the higher affinity site is located in the amino-terminal 1-14 amino acids [14] .
Previous studies have shown that the NoLS in ARF is important for its ability to inactivate MDM2 [11, 12] . We therefore examined the subcellular localization of the p14 ARF fragments in U2OS ( Figure 2 ) and MCF-7 cells (data not shown) by comparing the localization of the Tx-ARF proteins with a nucleolar protein, B23. The thioredoxin protein containing full-length p14 ARF (Tx-ARF1-132) was localized to the nucleolus like the wild-type protein (Figure 2a-d) . Analysis of proteins containing amino-terminal p14 ARF peptides showed that each protein that contained the first 22 amino acids localized to the nucleolus (Figure 2e -h,k,l). In contrast, constructs expressing p14 ARF peptides that failed to interact with MDM2 (Tx-ARF35-64, Tx-ARF23-44 and Tx-ARF56-64) also failed to localize to the nucleolus (Figure 2i ,j,m-p). These proteins showed general nucleoplasmic staining with some evidence of nucleolar exclusion. Expression of the exon-2-encoded sequence of p14 ARF (Tx-ARF65-132), containing the previously identified NoLS between amino acids 82-101 [11] , also showed some nucleolar localization, as expected, although significant nucleoplasmic staining was seen for this construct in all cells (Figure 2q ,r). All of these proteins showed the same patterns of subcellular localization in MDM2/p53 null mouse embryo fibroblasts (Supplementary material and data not shown), indicating that their localization was not dependent on the NoLS recently described in MDM2 [13, 14] . The identification of a previously undescribed NoLS in the amino terminus of p14 ARF is consistent with a recent study showing that deletion of the amino-terminal 14 amino acids of p14 ARF severely compromises nucleolar localization [14] .
The ability of ARF to inhibit MDM2 activity has been associated with both binding of ARF to MDM2 and the nucleolar localization of the ARF-MDM2 complex [12, 13] . We therefore examined the effect of the p14 ARF fragments on the subcellular localization of transfected and endogenous human MDM2 (Figure 3 and data not shown), and obtained identical results. Cotransfection of full-length p14 ARF in Tx-ARF1-132 resulted in a clear relocalization of MDM2 from the nucleoplasm to the nucleolus (Figure 3a-d) , in agreement with the previously described function of the mouse and human proteins [12, 13] . Expression of each of the amino-terminal Tx-ARF proteins that retained the ability to bind MDM2 and localize to the nucleolus also resulted in relocalization of MDM2 to the nucleolus (Figure 3e amino acids, retains some weak activity in relocalizing MDM2 to the nucleolus [14] , possibly reflecting a contribution of other exon-1β-encoded sequences. Defects in nucleolar localization have also been reported in fulllength p14 ARF proteins mutated in the carboxy-terminal NoLS [11] , and the nuclear localization signals in the thioredoxin proteins may contribute to the efficiency of nucleolar localization. Taken together, these studies suggest that, although both amino-and carboxy-terminal regions of 14 ARF contribute to the binding and relocalization of MDM2, the principal activity resides in the amino-terminal domain encompassing residues 1-22, which is also the region of ARF most highly conserved between species.
The localization of MDM2 to the nucleolus has been shown to correlate with inhibition of the ability to target p53 for degradation [12] , although in vitro assays suggest that the binding of ARF to MDM2 can directly inhibit the E3 ubiquitin ligase activity of MDM2 [2] . We therefore examined the ability of the p14 ARF peptides to prevent MDM2-mediated degradation of p53 by cotransfecting them into cells with p53 and MDM2. MDM2-mediated degradation of p53 was efficiently inhibited by coexpression of full-length p14 ARF (Figure 4a) . Analysis of smaller regions of p14 ARF showed that each amino-terminal p14 ARF peptide that retained the ability to bind and relocalize MDM2 to the nucleolus inhibited the degradation of p53 (Figure 4a ), although the smallest peptide (1-22) was reproducibly slightly less efficient than the full-length protein. In contrast, proteins containing p14 ARF peptides that failed to bind MDM2 (Tx-ARF35-64 and Tx-ARF56-64) did not prevent MDM2-mediated degradation of p53 (Figure 4a ). The exon-2-encoded sequences of p14 ARF in Tx-ARF65-132 also showed some ability to inhibit MDM2-mediated degradation of p53, although this was considerably less efficient than exon-1β-encoded sequences in Tx-ARF1-64 (Figure 4b ) or the amino-terminal peptide in Tx-ARF1-22 (Figure 4c ). In addition to targeting p53 for degradation, MDM2 also regulates its own stability, and full-length ARF can stabilize MDM2 in Brief Communication 541
Figure 3
The p14 ARF -dependent nucleolar relocalization of MDM2. U2OS cells were transfected with constructs encoding MDM2 and the indicated p14 ARF fragments. MDM2 localization was analyzed using (a,c,e,g,i,k,m,o,q) antibody Ab-1 and FITC-conjugated anti-mouse Ig antibody, and compared with (b,d,f,h,j,l,n,p,r) the nucleolar staining of the anti-B23-antibody visualized with Cy3-conjugated anti-goat Ig antibody.
Figure 4
Tx-ARF proteins that relocalize and bind to MDM2 also inhibit MDM2-mediated p53 degradation. (a) U2OS cells were transfected with constructs expressing a FLAG epitope-tagged p53 fusion protein (FLAG-p53), MDM2, the indicated Tx-ARF fusion proteins and the green fluorescent protein (GFP). Protein expression was analyzed by western blotting using an anti-FLAG antibody to detect FLAG-p53, rabbit serum IP1 to detect p14 ARF , and an anti-Myc antibody to detect Tx-ARF proteins. Equal expression of GFP confirmed equal transfection efficiencies. (b) U2OS cells were transfected with constructs expressing FLAG-p53, MDM2, Tx-ARF1-64 and Tx-ARF65-132 as indicated. Protein expression was analyzed by western blotting using an anti-FLAG antibody to detect FLAG-p53, and an anti-Myc antibody to detect the Tx-ARF proteins. (c) U2OS cells were transfected with constructs expressing FLAG-p53, MDM2, full-length ARF, Tx-ARF1-22 or Tx-ARF65-132 as indicated, and GFP. Protein expression was analyzed by western blotting using antibody SMP14 to detect MDM2, and an anti-FLAG antibody to detect FLAG-p53. Equal expression of GFP confirmed equal transfection efficiencies.
these experiments (Figure 4c ) under conditions where transfection of MDM2 alone barely increases the overall protein levels. The amino-terminal 1-22 p14 ARF peptide that drove nucleolar localization of MDM2 also stabilized MDM2, whereas Tx-ARF65-132, which was unable to relocalize MDM2 from the nucleoplasm, only weakly affected MDM2 stability. These results support the importance of nucleolar localization for efficient inhibition of MDM2-mediated degradation of p53. The degradation activity of MDM2 could, however, be slightly inhibited by Tx-ARF65-132 without efficient relocalization of MDM2 to the nucleolus.
We have shown that a peptide derived from the aminoterminal 22 amino acids of p14 ARF is sufficient to bind and inhibit the degradation function of MDM2, drive relocalization of MDM2 to the nucleolus and stabilize transcriptionally active p53. The physiological role of the newly identified amino-terminal NoLS in ARF is supported by a naturally occurring germ-line mutation that results in the expression of a fusion between amino acids 1-88 of p14 ARF and the carboxyl terminus of p16. This protein inhibits MDM2 activity as efficiently as the wild-type p14 ARF protein and localizes to the nucleolus, despite the loss of the previously described exon-2 encoded NoLS (S. Brookes, S. Llanos and G. Peters, personal communication). It is becoming apparent that many human tumors that retain wild-type p53 suffer loss of p14 ARF , and are therefore unable to activate p53 in response to abnormal proliferative signals. Inhibition of MDM2-mediated degradation of p53 in these cells may have therapeutic benefit, and attempts have been made to directly inhibit the interaction of MDM2 with p53. Our results present an alternative possibility, where peptides like p14 ARF 1-22 or small molecules that interact with the p14 ARF -binding region of MDM2 could drive nucleolar localization of MDM2 and provide an alternative mechanism through which to activate p53 in some tumors.
Materials and methods

Plasmids
The backbone Tx vector has been described previously [13] . Construction of the Tx-ARF constructs is described in the Supplementary material. Plasmids encoding human MDM2, human p53 and p14 ARF have been described previously [6, 16] . Plasmid pEGFP N1 encoding GFP was obtained from Clontech.
Protein analysis and immunofluorescence
The source of the antibodies used is described in the Supplementary material. Coimmunoprecipitation to examine protein-protein association, western blotting to determine total protein expression and immunofluorescence to identify sub-cellular localization of the proteins are described in the Supplementary material.
Supplementary material
Supplementary material including additional methodological detail and a figure showing subnuclear distributions of p14 ARF peptides in mouse embryo fibroblasts carrying null mutations in the p53 and MDM2 genes is available at http://current-biology.com/supmat/supmatin.htm.
